A mechanism description cannot replace a safety assessment. Saying that a compound preferentially acts at a receptor describes one aspect of its pharmacology. It does not establish that the desired effect is the only effect, or that every formulation and exposure will be well tolerated.
The afamelanotide prescribing information includes adverse reactions and a serious hypersensitivity warning. These are enough to reject the blanket description “side-effect free.” They do not, by themselves, quantify a comparison with melanotan II or establish what happened after an uncertain research-product exposure.
The randomized EPP trials assessed safety alongside clinical outcomes. That pairing is important. A treatment may have a worthwhile benefit-risk balance for a particular disease without having no risk. Removing the disease context can change the balance that originally justified medical use.
Comparative language needs its own evidence. “Cleaner,” “gentler” and “more selective” are often used as though they mean the same thing. They do not. A receptor experiment, a controlled adverse-event comparison and a patient's subjective experience answer different questions. A difference in chemical structure also does not supply a numerical risk ranking.
There is another distinction between expected symptoms and severe reactions. A person should not assume that any symptom after exposure is merely the usual transient effect because that is how a forum describes the compound. Trouble breathing, swelling or collapse requires urgent medical attention, not an attempt to verify receptor selectivity online.
For prescribed SCENESSE, safety questions belong with the treating clinician. For a research-labelled product, uncertainty about contents adds a separate concern that a licensed medicine's trial record cannot resolve. Neither circumstance supports experimenting with additional exposure to see whether a reaction disappears.
The useful takeaway is not that all melanocortin compounds are identical. It is that meaningful differences must be demonstrated with the right evidence. Pharmacology can explain why researchers investigate an intervention; it cannot certify a symptom-free experience, authenticate a vial or replace clinical evaluation of an adverse event.